Teilo Schaller, M.Sc., is a highly talented scientist with with a focus on cancer immunotherapy development. Teilo's leadership, R&D skills, ability to communicate professionally, and unending ambition make him a vital asset.
Over the past years, Teilo has contributed to a number of immunotherapies that are in active clinical development, including the bispecific antibody (CEA CD3 TCB) RG7802 for the treatment of colorectal cancer, a pp65-Dendritic Cell Vaccination for the treatment of glioblastoma, and two EGFRvIII-targeted bispecific T-cell engagers for the treatment of malignant brain tumors.
Current Appointments & Affiliations
Some information on this profile has been compiled automatically from
Duke databases and external sources. (Our
About page explains how this works.)
If you see a problem with the information, please write to
Scholars@Duke and let us know. We will